Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 7, 2011, Pages 616-618

  Penaloza, Andrea ^a   Vekemans, Marie Christiane ^b   Lambert, Catherine ^b   Hermans, Cedric ^b  

^a Accidents and Emergency Unit   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

deep vein thrombosis; hereditary haemorrhagic telengectasia; thalidomide

Indexed keywords

ENOXAPARIN; IRON; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE;

ADULT; ANEMIA; ANTICOAGULATION; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FEMALE; GENE MUTATION; HUMAN; IRON THERAPY; LEG PAIN; LEG SWELLING; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; THROMBOGENICITY; TREATMENT PLANNING;

ACTIVIN RECEPTORS, TYPE II; EPISTAXIS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 80053582147     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834a040c     Document Type: Article

References (16)

1. Sharathkumar AA, Shapiro A. Hereditary haemorrhagic telangiectasia. Haemophilia 2008; 14:1269-1280.
2. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17:860-871.
3. Van Cutsem E, Rutgeerts P, Geboes K, et al. Estrogen-progesterone treatment of Osler-Weber-Rendu disease. Clin Gastroenterol 1988; 10:676-679. (Pubitemid 19008999)
4. Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161:767. (Pubitemid 32200234)
5. Sabbà C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:926.
6. Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119:988-992.
7. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16:420-428.
8. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83:416-420. (Pubitemid 30148355)
9. Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 2010; 84:484-492.
10. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97:1031-1036.
11. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009; 22:115-128.
12. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27:4865-4873.
13. Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98:1031-1039. (Pubitemid 350091132)
14. Stief TW. Thrombin generation by thalidomide. Hemostasis Laboratory 2010; 3:201-207.
15. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919-4926.
16. Stief TW. 20% EXCA (0.1 IU/ml thrombin): the ideal anticoagulant target value. Hemostasis Laboratory 2011; 4:1-4.